ClinicalTrials.gg
RecruitingNCT06370962CHRONO-MUCOUpdated Sep 20, 2024

Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators

An observational study in Cystic Fibrosis, sponsored by Hospices Civils de Lyon. Recruiting at 3 sites in France. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Cystic Fibrosis by Hospices Civils de Lyon — 10 open to participants now, 11 under way, none of them phase 3. Cystic Fibrosis · Hospices Civils de Lyon.

Planned enrollment
10th of 22
180 · median 160
Started
2024
with 2 others
Observational
22 of 35
6 open now
Primary completion
2025-10
later than 5 of 10 live
Registered
31st of 35
by date

Among the 35 studies in Cystic Fibrosis by Hospices Civils de Lyon, this one is the 10th largest by planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2024, is one of 22 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 31st registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

10 of the 35 studies in Cystic Fibrosis by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Cystic Fibrosis by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Cystic fibrosis (CF) is a rare disease affecting one out of 4,500 newborns in France (INSERM 2021). Despite major advances in patient care over the past two decades, with significant improvements in life expectancy, cystic fibrosis remains a pathology that considerably impairs quality of life.

Several studies have reported the possibility of respiratory and non-respiratory sleep disorders (SD) in patients with CF. Respiratory disorders are reported to affect 30% of children with CF (Barbosa 2020). Among non-respiratory SD, sleep onset and maintenance insomnia are well known in these patients, while chronotype abnormalities (circadian rhythm disorders) are understudied. Chronotype refers to a person's tendency to be more efficient in the morning or evening.

The existence of chronotype abnormalities has been suggested in CF patients, but no precise data are available (Louis 2022). The involvement of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein dysfunction in the central nervous system (CNS) has been hypothesized as a contributory factor. In vivo, in a mouse model of CF, dysregulation of clock genes such as Clock, Cry2 and Per2 was found in the CNS (Barbato 2019). Among them, certain genes such as Rev-erbα could regulate endobronchial inflammation and contribute to the severity of respiratory pathology. All in all, chronotype abnormalities could be at the origin of sleep debt, impaired cognitive functions or metabolic disturbances.

In the era of highly effective modulator therapy (HEMT) for the treatment of CF, the impact of these new therapies on chronotype has been understudied. Assuming that chronotype abnormalities are a direct consequence of CFTR protein dysfunction in the retina and anterior hypothalamus, HEMT should improve sleep quality. However, between 20% and 30% of adult and pediatric patients express an increase in chronotype abnormalities following initiation of treatment.

Paradoxically, the perceived gain in respiratory quality of life is counterbalanced by the occurrence of these disorders. Some patients would effectively reverse their treatment in order to limit the phenomenon. A single polysomnographic study evaluated the effect of HEMT Kaftrio-Kalydeco on sleep in adults with CF (Welsner 2022). After 3 months of treatment, patients had a significant reduction in respiratory events, with no change in total sleep time, sleep efficiency or sleep architecture. Chronotype was not mentioned. Currently, no studies on chronotype in children or adults with CF have been carried out. Our hypothesis is that CF patients treated with HEMT would develop an abnormal chronotype of late sleep onset.

The aim of this study is to evaluate the chronotype of children with CF treated with HEMT. Chronotype abnormalities could have major consequences for quality of life, the immune system, cognitive functions and metabolism. Systematic detection of these disorders via anamnesis, followed by diagnosis by questionnaire, actimetrics and/or urinary melatonin dosage, would enable their early management, starting with the reversal of Kaftrio-Kalydeco intake between morning and evening.

03

Conditions studied

  • Cystic Fibrosis

Keywords

  • cystic fibrosis
  • Cystic fibrosis transmembrane conductance regulator modulators
  • circadian rhythm disorders
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be selected from Cystic Fibrosis Resource and Skill Centres of pediatric tertiary care hospitals (Lyon, Paris-Trousseau, Nancy).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with cystic fibrosis
  • Aged from 2 to 17 years and 11 months
  • Treated with CFTR modulator Kaftrio-Kalydeco from at least 2 months
  • Followed in Lyon, Paris-Trousseau or Nancy Cystic Fibrosis Resource and Skill Centres
  • Non-opposition from both parents

Exclusion criteria

Exclusion Criteria:

  • Parental refusal
  • Parents unable to comply with protocol requirements at investigator's discretion
  • Subject participating in interventional research with an exclusion period still in progress at the time of inclusion
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Children and adolescents with cystic fibrosis treated with Kaftrio-Kalydeco

    Patients with cystic fibrosis Aged from 2 to 17 years and 11 months Treated with CFTR modulator Kaftrio-Kalydeco for at least 2 months Followed in a participating Cystic Fibrosis Resource and Skill national Centre

06

What researchers measure

Primary outcomes

  1. Result of the Horne and Ostberg questionnaire.

    The frequency of each chronotype (normal, morning or evening) in patients with CF on HEMT will be determined by the result of the Horne and Ostberg questionnaire. The frequency of each chronotype will be summarized for all CF patients on HEMT using the following descriptive statistics: frequencies and percentages for each level of the variable (normal, morning or evening) and the number of missing values (missing values will be counted but not included in the denominator of the frequency calculation). Scores from 5 to 25: 21-25 = clearly morning; 18-20 = moderately morning; 12-17 = nor morning, neither evening; 9-11: moderately evening; 5-8: clearly evening.

    Time frame: Day 0

07

Study locations

1 of 3 sites recruiting
  • Hôpital Femme Mère Enfant
    Bron, 69677, France
    Recruiting
  • Service de pédiatrie, CHRU de Nancy - Hôpitaux de Brabois
    Nancy, 54500, France
    Not yet recruiting
    • Iulia IOAN, MD · Contactic.ioan@chru-nancy.fr · 03.83.15.47.94
    • Iulia IOAN, MD · Principal investigator
  • Service de pneumologie pédiatrique, Hôpital Armand Trousseau
    Paris, 75012, France
    Not yet recruiting
    • Jessica TAYTARD, MD · Contactjessica.taytard@aphp.fr · 01 44 73 63 46
    • Jessica TAYTARD, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2025, 18 months after the start.

Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's planned 18 months is below that.

Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Apr 17, 2024
StartActual
Apr 29, 2024
Primary completionEst.
Oct 29, 2025
CompletionEst.
Jan 29, 2026
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06370962
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Apr 29, 2024
Primary completion
Oct 29, 2025 (estimated)
Completion
Jan 29, 2026 (estimated)
Last update
Sep 20, 2024

Study contacts

Laurianne COUTIER, MD
Contact
laurianne.coutie@chu-lyon.fr
04 27 85 50 42 ext. +33
Catherine CHEN, MD
Contact
catherine.chen@chu-lyon.fr
04 27 85 50 42 ext. +33
Laurianne COUTIER, MD
principal investigator · Service de pneumologie, allergologie, mucoviscidose, Hôpital Femme Mère Enfant, HCL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion